Description

Gemcitabine Injection Accord (200mg) is utilized in the therapy of pancreatic malignancy, ovarian disease, bosom malignant growth, urinary bladder malignancy, and non-little cell cellular breakdown in the lungs.

Gemcitabine Injection Accord (200mg)

meddles with the development of DNA and RNA in the malignancy cells by subbing their structure blocks. It keeps the malignant growth cells from developing and increasing.

Common side effects of Gemcitabine:

Queasiness, Vomiting, Loss of craving, Hair misfortune, Low blood platelets, Allergic response, Breathlessness, Decreased white platelet check, Increased liver chemicals, Anemia (low number of red platelets), Flu-like manifestations, Blood in pee, Skin rash, Protein in pee.

What cancer does gemcitabine treat?

Gemcitabine, a pyrimidine nucleoside antimtabolite, is quite possibly the most encouraging new cytotoxic specialist. The medication has shown movement in an assortment of strong tumors and has been affirmed for the therapy of non-little cell cellular breakdown in the lungs, pancreatic, bladder, and bosom malignant growth.